SG10201908089VA - Novel dosing regimens of celgosivir for the treatment of dengue - Google Patents
Novel dosing regimens of celgosivir for the treatment of dengueInfo
- Publication number
- SG10201908089VA SG10201908089VA SG10201908089VA SG10201908089VA SG 10201908089V A SG10201908089V A SG 10201908089VA SG 10201908089V A SG10201908089V A SG 10201908089VA SG 10201908089V A SG10201908089V A SG 10201908089VA
- Authority
- SG
- Singapore
- Prior art keywords
- dengue
- celgosivir
- treatment
- dosing regimens
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Novel Dosing Regimens of Celgosivir For The Treatment of Dengue Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): OH (I) A compound of Formula (I) can be administered within onset of fever to hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENVl-4 viral infections. FIG. 1 61
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361798100P | 2013-03-15 | 2013-03-15 | |
US201361911795P | 2013-12-04 | 2013-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201908089VA true SG10201908089VA (en) | 2019-10-30 |
Family
ID=51537558
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201908089V SG10201908089VA (en) | 2013-03-15 | 2014-03-14 | Novel dosing regimens of celgosivir for the treatment of dengue |
SG11201507254VA SG11201507254VA (en) | 2013-03-15 | 2014-03-14 | Novel dosing regimens of celgosivir for the treatment of dengue |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507254VA SG11201507254VA (en) | 2013-03-15 | 2014-03-14 | Novel dosing regimens of celgosivir for the treatment of dengue |
Country Status (8)
Country | Link |
---|---|
US (3) | US9763921B2 (en) |
AU (1) | AU2014228035B2 (en) |
BR (1) | BR112015023806A2 (en) |
MX (1) | MX2015013115A (en) |
MY (1) | MY170991A (en) |
PH (1) | PH12015502128A1 (en) |
SG (2) | SG10201908089VA (en) |
WO (1) | WO2014143907A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201908089VA (en) * | 2013-03-15 | 2019-10-30 | 60 Pharmaceuticals Llc | Novel dosing regimens of celgosivir for the treatment of dengue |
US11000516B2 (en) * | 2015-12-11 | 2021-05-11 | 60 Degrees Pharmaceuticals, LLC | Dosing regimens of celgosivir for the prevention of dengue |
WO2018017426A1 (en) | 2016-07-16 | 2018-01-25 | Florida State University Research Foundation, Inc. | Compounds and methods for treatment and prevention of flavivirus infection |
US10555942B2 (en) | 2017-10-10 | 2020-02-11 | Florida State University Research Foundation, Inc. | Emetine compounds for treatment and prevention of flavivirus infection |
US11369592B2 (en) | 2020-02-21 | 2022-06-28 | Florida State University Research Foundation, Inc. | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001234596A1 (en) | 2000-01-28 | 2001-08-07 | Timothy M Block | Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections |
GB0110832D0 (en) * | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
GB0401238D0 (en) | 2004-01-21 | 2004-02-25 | Molecularnature Ltd | Immunomodulatory alkaloids |
SG10201908089VA (en) * | 2013-03-15 | 2019-10-30 | 60 Pharmaceuticals Llc | Novel dosing regimens of celgosivir for the treatment of dengue |
-
2014
- 2014-03-14 SG SG10201908089V patent/SG10201908089VA/en unknown
- 2014-03-14 BR BR112015023806A patent/BR112015023806A2/en not_active Application Discontinuation
- 2014-03-14 MY MYPI2015002372A patent/MY170991A/en unknown
- 2014-03-14 US US14/772,873 patent/US9763921B2/en active Active
- 2014-03-14 WO PCT/US2014/028076 patent/WO2014143907A1/en active Application Filing
- 2014-03-14 AU AU2014228035A patent/AU2014228035B2/en active Active
- 2014-03-14 SG SG11201507254VA patent/SG11201507254VA/en unknown
- 2014-03-14 MX MX2015013115A patent/MX2015013115A/en unknown
-
2015
- 2015-09-15 PH PH12015502128A patent/PH12015502128A1/en unknown
-
2017
- 2017-09-18 US US15/706,845 patent/US10517854B2/en active Active
-
2019
- 2019-12-23 US US16/725,387 patent/US11219616B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160030403A1 (en) | 2016-02-04 |
BR112015023806A2 (en) | 2017-08-22 |
AU2014228035A1 (en) | 2015-09-24 |
US11219616B2 (en) | 2022-01-11 |
US20180064693A1 (en) | 2018-03-08 |
WO2014143907A1 (en) | 2014-09-18 |
SG11201507254VA (en) | 2015-10-29 |
US10517854B2 (en) | 2019-12-31 |
MX2015013115A (en) | 2016-06-21 |
PH12015502128A1 (en) | 2016-01-25 |
US9763921B2 (en) | 2017-09-19 |
MY170991A (en) | 2019-09-23 |
US20200338050A1 (en) | 2020-10-29 |
AU2014228035B2 (en) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502318A1 (en) | Cyclic di-nucleotides as modulators of sting | |
NZ751197A (en) | Compounds and methods of treating infections | |
BR112017016006A2 (en) | compound, pharmaceutical composition, method of treating diseases and conditions, use of a compound and a combination, and, combination. | |
EA201590457A1 (en) | SULFAMOIL-Arylamides and Their Use as Medicinal Products for the Treatment of Hepatitis B | |
TW201613885A (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
EA201592200A1 (en) | DERIVATIVES OF SULFAMOILPYRROLAMIDE AND THEIR APPLICATION AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
MX2013003634A (en) | Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases. | |
PH12016502355A1 (en) | Pharmaceutical composition | |
PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
MY183534A (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
MX2016004492A (en) | Inhibitors of human immunodeficiency virus replication. | |
PH12015502230B1 (en) | Novel viral replication inhibitors | |
PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
PH12016502352A1 (en) | Pharmaceutical composition | |
NZ607580A (en) | N-heteroaryl compounds | |
TW201613578A (en) | Pharmaceutical combinations | |
MX2021006156A (en) | Compounds useful in hiv therapy. | |
BR112017002449A2 (en) | treatment of symptoms associated with androgen deprivation therapy | |
TW201613939A (en) | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | |
MX2019004200A (en) | Combination therapy. | |
WO2014140680A8 (en) | Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection | |
EA201990553A1 (en) | APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY | |
UA99793U (en) | METHOD OF TREATMENT OF RECURRING NOSE BLEEDING IN CHILDREN WITH TYPE 1 DIABETES | |
IN2013MU01155A (en) |